Updated on 7 September 2026
WPD Pharmaceuticals is seeking EUR 2–4 million in strategic investment to advance its lead programme, WPD401, through IND-enabling development
About
WPD Pharmaceuticals is seeking EUR 2–4 million in strategic investment to advance its lead programme, WPD401, through IND-enabling development and Phase I clinical proof of concept in recurrent glioblastoma. The investment provides exposure to a differentiated multi-targeted oncology platform with additional opportunities in blood–brain barrier delivery, theranostics and other receptor-positive solid tumors. The key near-term value inflection point is first-in-human validation of WPD401, with subsequent potential for pharma partnering, out-licensing or co-development.
Stage
- Startup
Applies to
- Healthcare